CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Having demonstrated that functionalization of PLGA nanoparticles with DY-635 sensitizes nanoparticles for CML cells and that DY-635 seems to be taken up predominantly by myeloid precursor cells in CML patients, we investigated further to determine whether DY-635-functionalized PLGA nanoparticles could distinguish between HSCs (CD34+/CD38−/CD26−) and LSCs (CD34+/CD38−/CD26+) in CML patients.